Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Inclusion Criteria: * Informed Consent * Body weight between 40 and 90 kg, inclusive. * Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB. * A chest X-ray compatible with TB. * Sputum positive * Adequate volume of sputum * Female participants of childbearing potential negative serum pregnancy and agree to use birth control * Male participants must agree to use contraception throughout participation in the trial and for 12 weeks after last dose. Exclusion Criteria: * Poor general condition * Rifampicin-resistant and/or Isoniazid-resistant * MTB Treatment received within the 3 months prior * Allergy to the IMP or related substances * Evidence of extrathoracic TB * A history of previous TB * Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease * History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic examination * Any evidence of renal impairment * For males, any evidence or history of abnormality in the reproductive system * History and/or presence (or evidence) of neuropathy or epilepsy. * Clinically relevant changes in the ECG * A history of or current clinically relevant cardiovascular disorder * Concomitant use of any drug known to prolong QTc interval * Diabetics using insulin * Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied). * Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP. * Any disease or conditions in which any of the medicinal products listed in the section pertaining to prohibited medication is used. * alcohol or drug abuse * Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the half-life of the IMP is unknown within 1 month. * Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks of cessation of treatment for males and within one week of cessation of treatment for females. * Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes * Any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing. * glucocorticoids within one year prior to dosing. * HIV infection with helper/inducer T lymphocyte (CD4 cell) count of less than or equal to 300x10-6/L. * Receiving antiretroviral therapy (ART).